3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Temozolomide
26
Magnetic Resonance Spectroscopy
19
Etoposide
12
Cyclophosphamide
12
Radiotherapy
11
Bevacizumab
10
Filgrastim
9
Biopsy
8
Carboplatin
7
X-Rays
6
Thiotepa
6
Specimen Handling
6
Phantoms, Imaging
6
Cisplatin
6
Carmustine
6
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Irinotecan
5
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
5
sargramostim
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
olaparib
3
etoposide phosphate
3
Vincristine
3
Surveys and Questionnaires
3
Lapatinib
3
Gadolinium DTPA
3
Azacitidine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
bempegaldesleukin
×
CNS
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts